Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 46, Issue 3, 2012, Pages 397-406

  D'Alessandro Gabazza, Corina N ^a   Kobayashi, Tetsu ^a   Boveda Ruiz, Daniel ^a   Takagi, Takehiro ^a   Toda, Masaaki ^a   Gil Bernabe, Paloma ^a   Miyake, Yasushi ^a   Yasukawa, Atsushi ^a   Matsuda, Yoshikazu ^a   Suzuki, Noboru ^a   Saito, Hiromitsu ^a   Yano, Yutaka ^a   Fukuda, Ayako ^b   Hasegawa, Tetsuya ^b   Toyobuku, Hidekazu ^b   Rennard, Stephen I ^c   Wagner, Peter D ^d   Morser, John ^e   Takei, Yoshiyuki ^a   Taguchi, Osamu ^a   Gabazza, Esteban C ^a   more..

^a MIE UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Growth factors; Idiopathic pulmonary fibrosis; RNA interference

Indexed keywords

BLEOMYCIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MOUSE; NONHUMAN; RNA SEQUENCE; SINGLE DRUG DOSE; SURVIVAL; TRANSGENIC MOUSE;

AEROSOLS; ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

MUS; MUS MUSCULUS; RODENTIA;

EID: 84863281562     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0158OC     Document Type: Article

References (45)

1. Verma S, Slutsky AS. Idiopathic pulmonary fibrosis: new insights. N Engl J Med 2007;356:1370-1372. (Pubitemid 46513307)
2. Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE Jr, Horne FM, Nayfield SG, Reynolds HY, et al. Workshop on idiopathic pulmonary fibrosis in older adults. Chest 2010;138:693-703.
3. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin Chest Med 2006;27:S11-S16, v.
4. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010;9:129-140.
5. Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest 2007;132:637-650. (Pubitemid 47282399)
6. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr, . A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-133. (Pubitemid 38056223)
7. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-829.
8. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-628.
9. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009;2:103-121.
10. The American Thoracic Society and the European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664.
11. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006;3:364-372. (Pubitemid 43845414)
12. Strieter RM. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 2005;128(Suppl 1)526S-532S.
13. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-525. (Pubitemid 32758505)
14. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-1081.
15. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358. (Pubitemid 30408720)
16. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. (Pubitemid 351160157)
17. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, Yehualaeshet T, Lu B, Flavell RA, Milbrandt J, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1- induced pulmonary fibrosis. J Exp Med 2004;200:377-389. (Pubitemid 39031256)
18. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovectormediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-776. (Pubitemid 27371693)
19. Khalil N, Parekh TV, O'Connor R, Antman N, Kepron W, Yehaulaeshet T, Xu YD, Gold LI. Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (t beta r-i and t beta r-ii) in idiopathic pulmonary fibrosis. Thorax 2001;56:907-915. (Pubitemid 33097184)
20. Fujimoto H, D'Alessandro-Gabazza CN, Palanki MS, Erdman PE, Takagi T, Gabazza EC, Bruno NE, Yano Y, Hayashi T, Tamaki S, et al. Inhibition of nuclear factor-kappab in T cells suppresses lung fibrosis. Am J Respir Crit Care Med 2007;176:1251-1260. (Pubitemid 350256479)
21. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-470. (Pubitemid 18098428)
22. Zhu Z, Ma B, Homer RJ, Zheng T, Elias JA. Use of the tetracyclinecontrolled transcriptional silencer (tts) to eliminate transgene leak in inducible overexpression transgenic mice. J Biol Chem 2001;276:25222-25229.
23. Abe K, Hazama M, Katoh H, Yamamura K, Suzuki M. Establishment of an efficient bac transgenesis protocol and its application to functional characterization of the mouse brachyury locus. Exp Anim 2004;53:311-320. (Pubitemid 41349898)
24. Giraldo P, Montoliu L. Size matters: use of yacs, bacs and pacs in transgenic animals. Transgenic Res 2001;10:83-103. (Pubitemid 32235229)
25. Zhou L, Dey CR, Wert SE, Whitsett JA. Arrested lung morphogenesis in transgenic mice bearing an SP-C-TGF-beta 1 chimeric gene. Dev Biol 1996;175:227-238.
26. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011;163:141-172.
27. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. Rnai therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711-719. (Pubitemid 44764213)
28. Castanotto D, Rossi JJ. The promises and pitfalls of RNA- interferencebased therapeutics. Nature 2009;457:426-433.
29. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-184.
30. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, Zhang X, Matthay MA, Ware LB, Homer RJ, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006;12:1286-1293. (Pubitemid 44706931)
31. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on sirna-based therapeutics. Nat Rev Drug Discov 2007;6:443-453. (Pubitemid 47064567)
32. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle 2006;5:2103-2109. (Pubitemid 44553744)
33. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176: 636-643. (Pubitemid 47503070)
34. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cellmediated self-reactivity. Nat Rev Immunol 2007;7:443-453. (Pubitemid 46834850)
35. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGFbeta1- mediated fibrosis. J Exp Med 2003;198:1179-1188. (Pubitemid 37323383)
36. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002;296:1646-1647.
37. Weiss CH, Budinger GR, Mutlu GM, Jain M. Proteasomal regulation of pulmonary fibrosis. Proc Am Thorac Soc 2010;7:77-83.
38. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, et al. Mice lacking smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999;1:260-266. (Pubitemid 129495775)
39. Roberts AB, Russo A, Felici A, Flanders KC. Smad3: a key player in pathogenetic mechanisms dependent on tgf-beta. Ann N Y Acad Sci 2003;995:1-10. (Pubitemid 36706609)
40. Behlke MA. Chemical modification of sirnas for in vivo use. Oligonucleotides 2008;18:305-319. (Pubitemid 352791344)
41. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K. Functional dissection of sirna sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008;36:2136-2151. (Pubitemid 351566989)
42. Oglesby IK, McElvaney NG, Greene CM. Micrornas in inflammatory lung disease: master regulators or target practice? Respir Res 2010;11: 148.
43. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E. Mir-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589-1597.
44. Robbins M, Judge A, MacLachlan I. Sirna and innate immunity. Oligonucleotides 2009;19:89-102.
45. de Fougerolles A, Novobrantseva T. Sirna and the lung: research tool or therapeutic drug? Curr Opin Pharmacol 2008;8:280-285.